Puma Biotechnology, Inc.

Puma Biotechnology, Inc. is a biopharmaceutical company focused on developing and commercializing products to improve cancer care. Its primary marketed product is NERLYNX, an oral version of neratinib, used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A, for treating hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. Puma sells its products through specialty pharmacy and distributor networks in the United States and globally.

Puma Biotechnology is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol PBYI. The company operates in the United States and its financial reporting currency is the US Dollar (USD). As a US-based company listed on a major US exchange, its stock is traded in USD, making it accessible to investors through US brokerage accounts.

Puma Biotechnology operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching, developing, and commercializing therapies for cancer, a field that involves complex biological processes and targeted treatments. The company's work in HER2-positive breast cancer and other oncology indications places it at the intersection of pharmaceutical development and molecular biology, typical of biotech firms that aim to bring innovative drugs to market.

Puma Biotechnology is headquartered in Los Angeles, California, United States. The company serves markets in the United States and globally. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib and related compounds. Additionally, it has sub-license agreements with partners such as Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd., which help distribute its products in various international markets.

Puma Biotechnology generates revenue primarily through the sale of its approved drug NERLYNX (neratinib) for the treatment of HER2-positive breast cancer. The company sells NERLYNX through specialty pharmacy and distributor networks in the United States. Internationally, it earns revenue through sub-license agreements with regional partners who commercialize the drug in their territories. These partners include Specialised Therapeutics Asia (for certain Asian markets), Medison Pharma (for Israel), Pint Pharma (for Latin America), Knight Therapeutics (for Canada), Pierre Fabre Medicament (for Europe and other regions), and Bixink Therapeutics (for China). The company also has a pipeline candidate, alisertib, which is in development for multiple cancer types and may generate future revenue if approved.